Free Cash Flow: A measure of financial performance calculated as operating cash flow minus capital expenditures. Calculated as: Cash Flow from Operations + Net Property, Plant & Equipment Exp (a negative number)
Immunovant, Inc. (IMVT) had Free Cash Flow of $-219.93M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-126.50M |
|
-- |
|
-- |
|
$131.76M |
|
$-131.76M |
|
$5.85M |
|
$-125.91M |
|
$-125.91M |
|
$-126.50M |
|
$-126.50M |
|
$-126.50M |
|
$-126.50M |
|
$-131.76M |
|
$-131.66M |
|
173.64M |
|
173.64M |
|
$-0.73 |
|
$-0.73 |
|
| Balance Sheet Financials | |
$573.55M |
|
$0.63M |
|
$9.41M |
|
$582.96M |
|
$63.25M |
|
-- |
|
-- |
|
$63.25M |
|
$519.71M |
|
$519.71M |
|
$519.71M |
|
174.53M |
|
| Cash Flow Statement Financials | |
$-219.93M |
|
-- |
|
$27.51M |
|
$713.97M |
|
$521.87M |
|
$-192.10M |
|
$31.87M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.07 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Free Cash Flow |
$-219.93M |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-24.34% |
|
-24.34% |
|
-21.70% |
|
-24.34% |
|
$2.98 |
|
$-1.27 |
|
$-1.27 |
|